PCSK9 inhibitors in clinical practice: Delivering on the promise?

In clinical trials, protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors robustly lowered LDL-cholesterol (LDL-c) and had a favorable tolerability and safety profile. Based on these findings, PCSK9 inhibitors are incorporated in updates of clinical treatment guidelines. However, trial resul...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Atherosclerosis 2018-03, Vol.270, p.205-210
Hauptverfasser:	Stoekenbroek, Robert M., Hartgers, Merel L., Rutte, Roger, de Wijer, Douwe D., Stroes, Erik S.G., Hovingh, G. Kees
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Anticholesteremic Agents - adverse effects Anticholesteremic Agents - therapeutic use Biomarkers - blood Cholesterol, LDL - blood Down-Regulation Familial hypercholesterolemia Female Humans Hypercholesterolemia Hyperlipoproteinemia Type II - blood Hyperlipoproteinemia Type II - diagnosis Hyperlipoproteinemia Type II - drug therapy Hyperlipoproteinemia Type II - enzymology Lipid-lowering drugs Male Middle Aged Netherlands PCSK9 inhibitors Proprotein Convertase 9 - antagonists & inhibitors Proprotein Convertase 9 - metabolism Serine Proteinase Inhibitors - adverse effects Serine Proteinase Inhibitors - therapeutic use Statin intolerance Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!